PlainPill

Modafinil

Also known as Provigil, Modalert

The short answer. People are split on Modafinil — 50% of 936 say it helped. It is most often used for focus: 86% of 689 reports say that improved. It is well studied — 155 meta-analyses on PubMed. The most common complaint is insomnia.

What users report
50%helped936 reports · high confidence
468 helped323 mixed145 didn't help

From 1,613 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
155
meta-analyses
297
RCTs
2,156
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Modafinil does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 155 meta-analyses on PubMed ↗ · 297 randomized trials ↗

Lancet Psychiatry · 2018 · Meta-analysis / systematic review
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.

PubMed 30097390 ↗
PLoS One · 2020 · Meta-analysis / systematic review
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis

Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu

PubMed 33085721 ↗
Registered clinical trials

218 human trials on ClinicalTrials.gov test Modafinil — 150 completed, 8 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US legal status (DEA)

Modafinil is a Schedule IV controlled substance in the US. DEA controlled-substance list ↗

FDA drug label

The current US prescription label has no boxed warning.

Full label on DailyMed (NIH) ↗

FDA recalls

2 recalls of products named for Modafinil. Most recent:

  • 2014-01-29 · Class II: Labeling: Label Mixup: MODAFINIL, Tablet, 200 mg may have potentially been mislabeled as one of the following drugs: OMEGA-3-ACID ETHYL ESTERS, Capsule,… record ↗
  • 2014-01-22 · Class II: Labeling:Label Mixup; MODAFINIL Tablet, 50 mg (1/2 of 100 mg Tablet) may be potentially mislabeled as SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg, NDC… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

32,100 adverse-event reports mention Modafinil. Most often reported:

  • Fatigue · 2,945
  • Nausea · 2,248
  • Drug ineffective · 2,140
  • Headache · 1,871
  • Fall · 1,791
  • Depression · 1,617

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Modafinil E — an unlikely cause of liver injury. LiverTox entry ↗

US government research funding (NIH)

NIH has funded 28 research projects with Modafinil in the title, $20,671,967 in total (1995–2019). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Modafinil ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

insomnia ×90anxiety ×75headache ×63tolerance ×37jitteriness ×28irritability ×1comedown ×1hair loss ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“It did make me focused and alert. I was working two jobs at the time and needed every ounce of energy I could muster.”
HelpedRead the discussion ↗
“I started experimenting with Modafinil recently - taking 200mg a day, first thing in the morning... This stuff genuinely makes me feel superhuman.”
MixedRead the discussion ↗
“I took 100mg modafinil yesterday and I worked very hard. Then I slept really well (I generally do after taking modafinil as long as I take it around 6-7am).”
MixedRead the discussion ↗
“The only med that works for my ADHD plus very little side effects.”
HelpedRead the discussion ↗
Read more Modafinil reviews →
Top discussions (5)

Modafinil compared

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate